Mode
Text Size
Log in / Sign up
Phase 3 N=109 Treatment

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

Pulmonary Embolism

Enrolled (actual)
109
Serious AEs
6.4%
Results posted
Apr 2023
Primary outcome: Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
The Bashir™ Endovascular Catheter (Device); r-tPA (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Thrombolex, Inc.
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy: RV/LV Ratio Difference
1.66; 1.10; -0.56
PRIMARY
Safety: Major Bleeding
1

Summary

To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.

Eligibility Criteria

Inclusion Criteria

  • Willing and able to provide informed consent;
  • Age 18 to ≤ 75 years of age;
  • PE symptom duration ≤ 14 days.
  • Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT (CTA);
  • RV/LV diameter ratio ≥ 0.9 by CTA as determined by the investigative site;
  • Willing and able to comply with all study procedures and follow-up.

Exclusion Criteria

  • CVA or TIA within one (1) year;
  • Head trauma, active intracranial, or intraspinal disease ≤ one (1) year prior to inclusion in the study;
  • Active bleeding from a major organ within one (1) month prior to inclusion in the study;
  • Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms);
  • Patients with bleeding diatheses;
  • Hematocrit 1.5 if currently on warfarin (Coumadin®);
  • aPTT > 50 seconds in the absence of anticoagulants;
  • Major surgery ≤ 14 days prior to inclusion in the study;
  • Serum creatinine > 2.0mg/dL;
  • Clinician deems high-risk for catastrophic bleeding;
  • History of heparin-induced thrombocytopenia (HIT Syndrome);
  • Pregnancy;
  • SBP 15 minutes within two (2) hours prior to BEC procedure and is not resolved with IV fluids;
  • Any vasopressor support;
  • Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution;
  • Evidence of irreversible neurological compromise;
  • Life expectancy 45kg/m2;
  • Absolute contraindication to anticoagulation;
  • Uncontrolled hypertension defined as SBP > 175mmHg and / or DBP > 110mmHg with pharmacotherapy within two (2) hours prior to inclusion in the study;
  • Currently participating in another study;
  • Any arterial line placement;
  • Current positive COVID diagnosis, or ≤ 8 weeks negative of COVID, or > 8 weeks from positive COVID test and with current symptoms, or current active viral pneumonia on chest CT scan;
  • In the opinion of the investigator, the subject is not a suitable candidate for the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04248868). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search